TY - JOUR
T1 - Polo-like kinase and survivin are esophageal tumor-specific promoters
AU - Sato, Fumiaki
AU - Abraham, John M.
AU - Yin, Jing
AU - Kan, Takatsugu
AU - Ito, Tetsuo
AU - Mori, Yuriko
AU - Hamilton, James P.
AU - Jin, Zhe
AU - Cheng, Yulan
AU - Paun, Bogdan
AU - Berki, Agnes T.
AU - Wang, Suna
AU - Shimada, Yutaka
AU - Meltzer, Stephen J.
N1 - Funding Information:
This article was supported by the American Gastroenterological Association/June and Donald O. Castell, MD, Clinical Esophageal Research Award, and USPHS Grants CA85069, CA01808, CA95323, CA98450, CA77057, CA106763, and a Grant-in-Aid from the Japanese Ministry of Education, Science and Culture, Sports, Science and Technology (Grants 12307026, 12470259, and 14370385).
Funding Information:
This article was supported by the American Gastroenterological Association/June and Donald O. Castell, MD, Clinical Esophageal Research Award, and USPHS Grants CA85069, CA01808, CA95323, CA98450, CA77057, the Veterans Affairs Office of Medical Research, and a Grant-in-Aid from the Japanese Ministry of Education, Science and Culture, Sports, Science and Technology (Grants 12307026, 12470259, and 14370385).
PY - 2006/4/7
Y1 - 2006/4/7
N2 - For developing successful cancer gene therapy strategies, tumor-specific gene delivery is essential. In this study, we used esophageal cancer (EC) cells to identify and evaluate esophageal tumor-specific gene promoters. Four genes (polo-like kinase-1/PLK, survivin/BIRC5, karyopherin α 2/KPNA2, and pituitary tumor transforming gene protein 1/PTTG1) were identified by a microarray analysis as highly expressed in EC cell lines vs. five normal organ tissues (liver, lung, kidney, brain, and heart). By quantitative RT-PCR, the average mRNA expression levels of these four genes in 20 primary ECs were 2.7-fold (PLK), 6.1-fold (survivin), 2.6-fold (KPNA2), and 2.4-fold (PTTG1) higher than that of each gene in 24 different normal organs. By dual luciferase assay, the promoter activity of PLK and survivin in EC cell lines was 18.9-fold and 28.5-fold higher, respectively, than in normal lung and renal cells. The promoters of PLK and survivin could be useful tools for developing EC-specific gene therapy vectors.
AB - For developing successful cancer gene therapy strategies, tumor-specific gene delivery is essential. In this study, we used esophageal cancer (EC) cells to identify and evaluate esophageal tumor-specific gene promoters. Four genes (polo-like kinase-1/PLK, survivin/BIRC5, karyopherin α 2/KPNA2, and pituitary tumor transforming gene protein 1/PTTG1) were identified by a microarray analysis as highly expressed in EC cell lines vs. five normal organ tissues (liver, lung, kidney, brain, and heart). By quantitative RT-PCR, the average mRNA expression levels of these four genes in 20 primary ECs were 2.7-fold (PLK), 6.1-fold (survivin), 2.6-fold (KPNA2), and 2.4-fold (PTTG1) higher than that of each gene in 24 different normal organs. By dual luciferase assay, the promoter activity of PLK and survivin in EC cell lines was 18.9-fold and 28.5-fold higher, respectively, than in normal lung and renal cells. The promoters of PLK and survivin could be useful tools for developing EC-specific gene therapy vectors.
KW - Esophageal cancer
KW - Gene therapy
KW - Microarray
KW - Tumor-specific promoter
UR - http://www.scopus.com/inward/record.url?scp=33344478035&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33344478035&partnerID=8YFLogxK
U2 - 10.1016/j.bbrc.2006.01.177
DO - 10.1016/j.bbrc.2006.01.177
M3 - Article
C2 - 16487489
AN - SCOPUS:33344478035
SN - 0006-291X
VL - 342
SP - 465
EP - 471
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 2
ER -